Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism

Oral Oncology

Volumn 47, Issue 11, 2011, Pages 1039-1047

  Galer, Chad E ^a   Sano, Daisuke ^a   Ghosh, Sukhen C ^a   Hah, Jeong H ^a   Auzenne, Edmund ^a   Hamir, Amirali N ^a   Myers, Jeffrey N ^a   Klostergaard, Jim ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CD44; HA paclitaxel; Orthotopic; SCCHN

Indexed keywords

HYALURONIC ACID; PACLITAXEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; HUMANS; HYALURONIC ACID; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; PACLITAXEL; TONGUE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 80054807276     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.07.029     Document Type: Article

References (62)

1. Society AC. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009.
2. A.L. Carvalho, M.K. Ikeda, J. Magrin, and L.P. Kowalski Trends of oral and oropharyngeal cancer survival over five decades in 3267 patients treated in a single institution Oral Oncol 40 1 2004 71 76 (Pubitemid 37510215)
3. M. Machtay, J. Moughan, and A. Trotti Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 21 2008 3582 3589
4. J. Bernier, C. Domenge, and M. Ozsahin Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 19 2004 1945 1952 (Pubitemid 38580197)
5. J.S. Cooper, T.F. Pajak, and A.A. Forastiere Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 19 2004 1937 1944
6. J.B. Vermorken, E. Remenar, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 17 2007 1695 1704 (Pubitemid 350005151)
7. M.R. Posner, D.M. Hershock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 17 2007 1705 1715 (Pubitemid 350005152)
8. J.W. Singer, S. Shaffer, and B. Baker Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane Anticancer Drugs 16 3 2005 243 254 (Pubitemid 40283939)
9. E. Auzenne, N.J. Donato, and C. Li Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma Clin Cancer Res 8 2 2002 573 581 (Pubitemid 34193979)
10. P. Bonomi Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer Expert Rev Anticancer Ther 7 4 2007 415 422 (Pubitemid 46681797)
11. C. Li, J.E. Price, and L. Milas Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors Clin Cancer Res 5 4 1999 891 897 (Pubitemid 29180842)
12. M.E. O'Brien, M.A. Socinski, and A.Y. Popovich Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer J Thorac Oncol 3 7 2008 728 734
13. K.S. Albain, C.P. Belani, P. Bonomi, K.J. O'Byrne, J.H. Schiller, and M. Socinski PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2 Clin Lung Cancer 7 6 2006 417 419 (Pubitemid 44043553)
14. C.J. Langer, K.J. O'Byrne, and M.A. Socinski Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer J Thorac Oncol 3 6 2008 623 630 (Pubitemid 351787307)
15. M.J. Gardner, J.B. Catterall, L.M. Jones, and G.A. Turner Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis Clin Exp Metastasis 14 4 1996 325 334 (Pubitemid 26363206)
16. E. Stickeler, I.B. Runnebaum, V.J. Mobus, D.G. Kieback, and R. Kreienberg Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines Anticancer Res 17 3C 1997 1871 1876 (Pubitemid 27320919)
17. T.K. Yeo, J.A. Nagy, K.T. Yeo, H.F. Dvorak, and B.P. Toole Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells Am J Pathol 148 6 1996 1733 1740 (Pubitemid 26170505)
18. S.J. Wang, G. Wong, A.M. de Heer, W. Xia, and L.Y. Bourguignon CD44 variant isoforms in head and neck squamous cell carcinoma progression Laryngoscope 119 8 2009 1518 1530
19. I. Fonseca, T. Pereira, J. Rosa-Santos, and J. Soares Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation J Surg Oncol 76 2 2001 115 120
20. Y. Luo, and G.D. Prestwich Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate Bioconjug Chem 10 5 1999 755 763 (Pubitemid 29456361)
21. E. Auzenne, S.C. Ghosh, and M. Khodadadian Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts Neoplasia 9 6 2007 479 486 (Pubitemid 46983450)
22. T.Y.A. Yokoi, T. Odajima, and K. Furukawa Establishment and characterization of a human cell line derived from a squamous cell carcinoma of the tongue Tumor Res 23 1988 43 57 (Pubitemid 19171025)
23. D. Sano, S. Choi, and Z.L. Milas The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue Arch Otolaryngol Head Neck Surg 135 4 2009 411 420
24. J. Knight, B.A. Gusterson, G. Cowley, and P. Monaghan Differentiation of normal and malignant human squamous epithelium in vivo and in vitro: a morphologic study Ultrastruct Pathol 7 2-3 1984 133 141 (Pubitemid 15075665)
25. Y. Luo, M.R. Ziebell, and G.D. Prestwich A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells Biomacromolecules 1 2 2000 208 218
26. W.J. Trickler, A.A. Nagvekar, and A.K. Dash The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel Pharm Res 26 8 2009 1963 1973
27. X. Wang, J. Zhu, and P. Zhao In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells Cancer Biol Ther 6 6 2007 980 987
28. H. Shen, D. Hu, and J. Du Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice Eur J Pharmacol 601 1-3 2008 23 29
29. A.V. Boddy, E.R. Plummer, and R. Todd A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules Clin Cancer Res 11 21 2005 7834 7840 (Pubitemid 41611628)
30. Z. Liu, K. Chen, and C. Davis Drug delivery with carbon nanotubes for in vivo cancer treatment Cancer Res 68 16 2008 6652 6660
31. E. Auzenne, N.J. Donato, C. Li, E. Leroux, R.E. Price, and D. Farquhar Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma Clin Cancer Res 8 2 2002 573 581 (Pubitemid 34193979)
32. W.M. Merritt, C.G. Danes, and M.M. Shahzad Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma Cancer Biol Ther 8 16 2009 1596 1603
33. M. Zhang, W. Tao, S. Pan, X. Sun, and H. Jiang Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts Anticancer Drugs 20 5 2009 355 363
34. S. Kesari, D. Schiff, and L. Doherty Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro Oncol 9 3 2007 354 363 (Pubitemid 47169667)
35. T. Nelius, T. Klatte, W. de Riese, A. Haynes, and S. Filleur Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy Med Oncol 27 2 2010 363 367
36. M. Caballero, J.J. Grau, and J.L. Blanch Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) paclitaxel treatment for advanced head and neck cancer Arch Otolaryngol Head Neck Surg 3 11 2007 1143 1148 (Pubitemid 350157028)
37. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res 62 23 2002 6938 6943 (Pubitemid 35424084)
38. J. Wang, P. Lou, R. Lesniewski, and J. Henkin Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly Anticancer Drugs 14 1 2003 13 19 (Pubitemid 36177350)
39. S.S. Ng, A. Sparreboom, and Y. Shaked Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel Clin Cancer Res 12 14 Pt 1 2006 4331 4338
40. S.S. Ng, W.D. Figg, and A. Sparreboom Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins Cancer Res 64 3 2004 821 824 (Pubitemid 38176878)
41. D.S. Yin, Z.Q. Ge, W.Y. Yang, C.X. Liu, and Y.J. Yuan Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid Cancer Lett 243 1 2006 71 79
42. A. Banzato, S. Bobisse, and M. Rondina A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity Clin Cancer Res 14 11 2008 3598 3606
43. C.J. Langer CT-2103: emerging utility and therapy for solid tumours Expert Opin Investig Drugs 13 11 2004 1501 1508 (Pubitemid 39530202)
44. L. Paz-Ares, H. Ross, and M. O'Brien Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer Br J Cancer 98 10 2008 1608 1613 (Pubitemid 351684693)
45. K. Greish, J. Fang, T. Inutsuka, A. Nagamitsu, and H. Maeda Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting Clin Pharmacokinet 42 13 2003 1089 1105 (Pubitemid 37357647)
46. B. Delpech, N. Girard, P. Bertrand, M.N. Courel, C. Chauzy, and A. Delpech Hyaluronan: fundamental principles and applications in cancer J Intern Med 242 1 1997 41 48 (Pubitemid 27323864)
47. V. Abetamann, H.F. Kern, and H.P. Elsasser Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells Clin Cancer Res 2 9 1996 1607 1618 (Pubitemid 126447457)
48. B. Mack, and O. Gires CD44s and CD44v6 expression in head and neck epithelia PLoS One 3 10 2008 e3360
49. H. Shigeishi, S. Fujimoto, and M. Hiraoka Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas Int J Oncol 34 6 2009 1565 1571
50. Y. Yamano, K. Uzawa, and K. Shinozuka Hyaluronan-mediated motility: a target in oral squamous cell carcinoma Int J Oncol 32 5 2008 1001 1009
51. A. Schmitt, T.F. Barth, and E. Beyer The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses Int J Oncol 34 3 2009 629 639
52. S.J. Wang, G. Wong, A.M. de Heer, W. Xia, and L.Y. Bourguignon CD44 variant isoforms in head and neck squamous cell carcinoma progression Laryngoscope 119 8 2009 1518 1530
53. J. Han, M. Kioi, W.S. Chu, J.L. Kasperbauer, S.E. Strome, and R.K. Puri Identification of potential therapeutic targets in human head & neck squamous cell carcinoma Head Neck Oncol 14 1 2009 1 27
54. S.M. Chang, R.D. Xing, F.M. Zhang, and Y.Q. Duan Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy Oral Dis 15 8 2009 570 572
55. L. Ailles, and M. Prince Cancer stem cells in head and neck squamous cell carcinoma Methods Mol Biol 568 2009 175 193
56. O. Pozdnyakova, M.M. Hoang, K.A. Dresser, and M. Mahalingam Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma Arch Pathol Lab Med 133 8 2009 1285 1290
57. W.K. Liu, Q. Fu, and Y.M. Li The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma Onkologie 32 10 2009 574 578
58. C. Torre, S.J. Wang, W. Xia, and L.Y. Bourguignon Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling Arch Otolaryngol Head Neck Surg 136 5 2010 493 501
59. V. Orian-Rousseau CD44, a therapeutic target for metastasising tumours Eur J Cancer 46 7 2010 1271 1277
60. J.T. Lin, T.H. Chang, and C.S. Chang Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer Oral Oncol 46 5 2010 e29 e33
61. P. Bidaud, J. Chasle, and F. Sichel Expression of p53 family members and CD44 in oral squamous cell carcinoma (OSCC) in relation to tumorigenesis Histol Histopathol 25 3 2010 331 339
62. H. Riechelmann, A. Sauter, and W. Golze Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma Oral Oncol 44 9 2008 823 829